Viking Therapeutics VKTX Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$158.33M-0.4% | -$157.66M-73.7% | -$90.79M-38.5% | -$65.56M-43.7% | -$45.63M-28.8% | ||
| $10.34M+20.4% | $8.59M+17.1% | $7.34M-45.8% | $13.55M+19.4% | $11.35M+100% | ||
| -$113.98M-33.6% | -$85.29M+9.3% | -$94M-99.7% | -$47.06M+10.1% | -$52.33M-67.8% | ||
| $54.19M-28.3% | $75.61M-52.7% | $160.03M+276% | $42.51M-32.8% | $63.25M— | ||
| $12.08M-83.9% | $75.1M+15,546% | $480K-5.3% | $507K+45.3% | $349K-65.1% | ||
| -$47.71M-173% | $65.43M-1.6% | $66.5M— | $0-100% | $11.26M+148% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Viking Therapeutics's cash flow data come from?
- Every line is extracted from Viking Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.